Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
Targeting replication stress in cancer therapy
AABA da Costa, D Chowdhury, GI Shapiro… - Nature reviews Drug …, 2023 - nature.com
Replication stress is a major cause of genomic instability and a crucial vulnerability of
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …
[HTML][HTML] Mechanisms controlling PD-L1 expression in cancer
The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene)
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …
PD-L1 degradation pathway and immunotherapy for cancer
Q Gou, C Dong, H Xu, B Khan, J Jin, Q Liu, J Shi… - Cell death & …, 2020 - nature.com
Programmed death ligand 1 (PD-L1, CD274) is an essential immune checkpoint protein that
binds to programmed death 1 (PD-1) on T-lymphocytes. T cell plays a critical role in killing …
binds to programmed death 1 (PD-1) on T-lymphocytes. T cell plays a critical role in killing …
[HTML][HTML] Genomic instability, inflammatory signaling and response to cancer immunotherapy
M Chen, R Linstra, MATM van Vugt - … et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
Genomic and chromosomal instability are hallmarks of cancer and shape the genomic
composition of cancer cells, thereby determining their behavior and response to treatment …
composition of cancer cells, thereby determining their behavior and response to treatment …
The DNA damage response and inflammation in cancer
Genomic stability in normal cells is crucial to avoid oncogenesis. Accordingly, multiple
components of the DNA damage response (DDR) operate as bona fide tumor suppressor …
components of the DNA damage response (DDR) operate as bona fide tumor suppressor …
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Significant technological advances in radiotherapy have been made in the past few
decades. High-precision radiotherapy has recently become popular and is contributing to …
decades. High-precision radiotherapy has recently become popular and is contributing to …
ATR inhibition induces CDK1–SPOP signaling and enhances anti–PD-L1 cytotoxicity in prostate cancer
Purpose: Despite significant benefit for other cancer subtypes, immune checkpoint blockade
(ICB) therapy has not yet been shown to significantly improve outcomes for men with …
(ICB) therapy has not yet been shown to significantly improve outcomes for men with …
[HTML][HTML] Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
SARS-CoV-2 has currently precipitated the COVID-19 global health crisis. We developed a
medium-throughput drug-screening system and identified a small-molecule library of 34 of …
medium-throughput drug-screening system and identified a small-molecule library of 34 of …